Benefit of Lidocaine Perfusion in Cancer Related Visceral Pain Resistant to Morphinics
Phase 3
- Conditions
- CancerPain
- Registration Number
- NCT00181012
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Brief Summary
This study will evaluate the benefit of lidocaine perfusion in cancer related visceral pain resistant to morphinics. It is an efficacy study in adults and children and a randomized prospective study.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
- Patients suffering from cancer of any type, at any stage, hospitalized at the Institut Gustave Roussy
- Aged from 6 to 14 years old (group A) and from 15 to 70 years old (adults)
- Presenting visceral pain due to neurotoxic chemotherapy, due to the tumoral mass or to peritoneal carcinosis
- Pain resistant to morphinic treatment
Exclusion Criteria
- Cardiac troubles, clinical cardiac insufficiency, or history of myocardial infarction (MI) of less than 3 months
- Neurological: non-controlled epilepsy, encephalopathy, or dementia
- Severe hepatic insufficiency
- Severe renal insufficiency
- Respiratory insufficiency
- Patients having surgery or in postoperative period
- Known deficit in G6PD, alanine exposure, or sulphamide treatment
- Porphyria
- Weight > 80 kg
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method To determine prospectively the lidocaine efficacy in 2 types of patient populations with cancer (group A: children from 6 to 14 years old and group B: adults from 15 to 70 years old) continuous intravenous perfusion for 6 days
- Secondary Outcome Measures
Name Time Method To confirm the tolerance of the lidocaine
Trial Locations
- Locations (1)
Institut Gustave-Roussy
🇫🇷Villejuif, France